Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Ralpha1 subunit. Abrezekimab can be used in research of asthma[1].
Molecular Weight:
(48.1 kDa)
Purity:
95.00
CAS Number:
[2043952-59-4]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted